Ann: Appendix 4C - quarterly, page-7

Had a look back at my notes, FY18 Average Quarterly OPEX was $700k.

So we need around 500% growth on quarterly receivables to shake off our current risk profile, which seems like a lot but is achievable when looking into CCP's addressable market.  

FGF have done well floating ACU & CyprotVault tokens, I wonder if they will circle back to CCP and provide more funding.

The waiting game is now in with KoolMax to spread our product across their client base, sadly dicker data have not come through and not much news from other channel partners either. My 'projection' is ~$1M in sales FY19 with cash positive mid-2020. 

Very much a high risk spec stock here, though solid management and world class product usually gets thing over the line